Due: August 4, 2025
The DxR2 program will solicit new point of care/remote-use products with domestic manufacturing capabilities which address test development for Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) biothreats to include glanders, botulism, tularemia, typhus, smallpox, and plague.
The overall goals of this program are to build a biothreat diagnostic portfolio, maintain domestic test manufacturing facilities, and to enable just-in-time manufacturing practices to be able to rapidly produce biothreat tests and needed supplies at scale, and to achieve aggressive test delivery schedules. The first phase of the DxR2 program will focus on the development and regulatory clearance of biothreat tests, and design transfer to manufacturing activities, such as limited production runs for validation, quality checks, stability studies, early adopter training, and manufacturing capacity studies. Additional phases may be added dependent upon program progress and available funding.
This opportunity requires membership in the Rapid Response Partnership Vehicle (RRPV). This Consortium releases numerous opportunities throughout the year, so even if this one may not be right for you, we strongly encourage you to join the consortium, so you are ready for the next opportunity.
Complete the form below and a program representative will reach out to you shortly to support you through the process.